Show simple item record

dc.contributor.authorMcNeish, I
dc.contributor.authorLedermann, J
dc.contributor.authorWebber, L
dc.contributor.authorJames, L
dc.contributor.authorKaye, S
dc.contributor.authorHall, M
dc.contributor.authorHall, G
dc.contributor.authorClamp, Andrew R
dc.contributor.authorEarl, H
dc.contributor.authorBanerjee, S
dc.contributor.authorKristeleit, R
dc.contributor.authorRaja, F
dc.contributor.authorFeeney, A
dc.contributor.authorLawrence, C
dc.contributor.authorDawson-Athey, L
dc.contributor.authorPersic, M
dc.contributor.authorKhan, I
dc.date.accessioned2014-09-04T09:10:34Z
dc.date.available2014-09-04T09:10:34Z
dc.date.issued2014-07-28
dc.identifier.citationA randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. 2014: Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid25070546
dc.identifier.doi10.1093/annonc/mdu363
dc.identifier.urihttp://hdl.handle.net/10541/325848
dc.description.abstractWe investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleA randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.en
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Sciences, University of Glasgow, Glasgow UKen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractWe investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.


This item appears in the following Collection(s)

Show simple item record